Ultragenyx Pharmaceutical Inc. — Form 8-K Summary
Business context and reporting period
On October 6, 2026, Ultragenyx entered into an agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV). The company received the voucher from the FDA on August 19, 2026, following approval of GENGLYCOS (pariglasgene brecaparvovec-opnr, also known as DTX401) for adult and pediatric patients aged eight years and older with glycogen storage disease type Ia.
Financial terms and metrics
- The buyer agreed to pay $210 million in cash upon closing.
- Under a 2018 patent license agreement with the U.S. Department of Health (NIH), Ultragenyx must pay NIH 20% of the sale’s gross proceeds after closing. Based on the stated price, that share would be $42 million; the filing does not state net proceeds.
- The filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics, or provide a prior-period comparison.
Outlook, conditions, and contingencies
The sale has not yet closed and remains subject to customary closing conditions, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The agreement includes customary representations, warranties, covenants, and indemnification provisions, subject to limitations. The filing provides no broader financial guidance or outlook.
Important facts for investors to verify
- Whether and when the transaction closes, and whether the $210 million payment is received.
- The amount and timing of the NIH payment and the resulting proceeds retained by Ultragenyx.
- The full agreement, which the company said it would file with its Form 10-K for the year ended December 31, 2026.